NASDAQ · ONCT
Oncternal Therapeutics, Inc.
$0.53-$0.17 (-24.12%)
Oncternal Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.04% below the high.
Loading market information…
AMEX · TMBR · USD
Stock price, earnings
Quote as of Nov 28, 2023, 08:59 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Timber Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.89% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Timber Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Timber Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the research, development, and market introduction of treatments for rare dermatological conditions. The company's key product candidates include: TMB-001, a patented topical isotretinoin formulation, which has successfully completed Phase 2b clinical trials. It is designed to address moderate to severe forms of Congenital Ichthyosis (CI), a group of uncommon genetic disorders affecting skin keratinization. TMB-002, a proprietary topical rapamycin, currently undergoing Phase 2b clinical trials. This therapy targets facial angiofibroma associated with Tuberous Sclerosis Complex, a complex genetic disorder characterized by the growth of benign tumors in multiple organs. TMB-003, a unique Sitaxsentan formulation functioning as a selective endothelin-A receptor antagonist, which is in preclinical development for various sclerotic skin diseases. Additionally, through a licensing agreement with AFT Pharmaceuticals Limited, Timber Pharmaceuticals is advancing two topical minocycline therapies: BPX-01, now in Phase 3 development for treating inflammatory lesions of acne vulgaris. BPX-04, which is prepared for Phase 3 trials, targeting papulopustular rosacea. Founded in 2019, Timber Pharmaceuticals is headquartered in Basking Ridge, New Jersey.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:31 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q3 2021 | Nov 15, 2021 | -$4.00 | $41.85K |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.53-$0.17 (-24.12%)
Oncternal Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.04% below the high.
$0.03$0.00 (0.0%)
Cassava Sciences, Inc. Warrant’s quoted price sits in the lower half of its reported 52-week range, 99.73% below the high.
$0.38-$0.01 (-1.56%)
NeuBase Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.49% below the high.
$0.41$0.00 (0.0%)
CohBar, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.41% below the high.
$0.30+$0.30 (+100.0%)
Altamira Therapeutics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.85% below the high.
$0.32-$0.17 (-34.28%)
InVivo Therapeutics Holdings Corporation’s quoted price sits in the lower half of its reported 52-week range, 86.64% below the high.
$0.04-$0.02 (-27.27%)
Impel Pharmaceuticals Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.05% below the high.
$0.07-$0.01 (-6.68%)
Bellicum Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 94.29% below the high.
